First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.

被引：1
|
作者：
Beslija, S. [1 ]
Brodowicz, T. [1 ]
Greil, R. [1 ]
Inbar, M. J. [1 ]
Kahan, Z. [1 ]
Kaufman, B. [1 ]
Lang, I. [1 ]
Steger, G. G. [1 ]
Stemmer, S. M. [1 ]
Zielinski, C. [1 ]
Zvirbule, Z. [1 ]
机构：
[1] CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/000B-5472.SABCS11-OT2-01-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-01-02
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study
    Dieras, Veronique
    Pop, Simona
    Berger, Frederique
    Dujaric, Marie-Eglantine
    Beuzeboc, Philippe
    Escalup, Laurence
    Bidard, Francois Clement
    Cottu, Paul Henri
    Le Tourneau, Christophe
    Piperno-Neumann, Sophie
    Laurence, Valerie
    Robain, Mathieu
    Asselain, Bernard
    Pierga, Jean-Yves
    ANTICANCER RESEARCH, 2017, 37 (03) : 1403 - 1407
  • [22] Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab
    Pizzuti, Laura
    Sergi, Domenico
    Sperduti, Isabella
    Di Lauro, Luigi
    Mazzotta, Marco
    Botti, Claudio
    Izzo, Fiorentino
    Marchetti, Luca
    Tomao, Silverio
    Marchetti, Paolo
    Natoli, Clara
    Grassadonia, Antonino
    Gamucci, Teresa
    Mentuccia, Lucia
    Magnolfi, Emanuela
    Vaccaro, Angela
    Cassano, Alessandra
    Rossi, Ernesto
    Botticelli, Andrea
    Sini, Valentina
    Sarobba, Maria G.
    Fabbri, Maria Agnese
    Moscetti, Luca
    Astone, Antonio
    Michelotti, Andrea
    De Angelis, Claudia
    Bertolini, Ilaria
    Angelini, Francesco
    Ciliberto, Gennaro
    Maugeri-Sacca, Marcello
    Giordano, Antonio
    Barba, Maddalena
    Vici, Patrizia
    CANCER BIOLOGY & THERAPY, 2018, 19 (04) : 328 - 334
  • [23] Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer
    Martin, Miguel
    Makhson, Anatoly
    Gligorov, Joseph
    Lichinitser, Mikhail
    Lluch, Ana
    Semiglazov, Vladimir
    Scotto, Nana
    Mitchell, Lada
    Tjulandin, Sergei
    ONCOLOGIST, 2012, 17 (04): : 469 - 475
  • [24] First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial
    Masuda, Norikazu
    Takahashi, Masato
    Nakagami, Kazuhiko
    Okumura, Yasuhiro
    Nakayama, Takahiro
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Tajima, Kosei
    Kashiwaba, Masahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (05) : 385 - 392
  • [25] Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer
    Borson, Rachel
    Harker, Graydon
    Reeves, James
    Beck, Thaddeus
    Hager, Steven
    Horvath, William
    Jones, Michael
    Tillinghast, Guy
    Arrowsmith, Edward
    Harrer, Grant
    Kudrik, Fred J.
    Malamud, Stephen C.
    Bromund, Jane
    Zeigler, Haoyue
    Tai, Datchen Fritz
    Kornberg, Lori J.
    Obasaju, Coleman
    Orlando, Mauro
    Yardley, Denise A.
    CLINICAL BREAST CANCER, 2012, 12 (05) : 322 - 330
  • [26] Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Vrdoljak, E.
    Marschner, N.
    Zielinski, C.
    Gligorov, J.
    Cortes, J.
    Puglisi, F.
    Aapro, M.
    Fallowfield, L.
    Fontana, A.
    Inbar, M.
    Kahan, Z.
    Welt, A.
    Levy, C.
    Brain, E.
    Pivot, X.
    Putzu, C.
    Gonzalez-Martin, A.
    Ebel, K.
    Easton, V.
    von Minckwitz, G.
    CANCER RESEARCH, 2016, 76
  • [27] Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer
    Wu, Qiuji
    Wang, Xinyuan
    Zhang, Mengxi
    Liao, Weiting
    Wang, Feng
    Li, Qiu
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (04) : 153 - 159
  • [28] INTERIM RESULTS OF A PHASE II STUDY OF NAB-PACLITAXEL, BEVACIZUMAB, AND GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Gluck, S.
    Lobo, C.
    Hurley, J.
    Lopes, G.
    Reis, I.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    Tukia, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 68 - 69
  • [29] Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)
    Miles, D. W.
    De Haas, S. L.
    Romieu, G.
    Chan, A.
    Dirix, L.
    Cortess, J.
    Delmar, P. R.
    Scherer, S. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S176 - S176
  • [30] A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
    Dieras, V.
    Jassem, J.
    Dirix, L. Y.
    Guastalla, J. P.
    Bono, P.
    Hurvitz, S. A.
    Goncalves, A.
    Romieu, G.
    Limentani, S. A.
    Jerusalem, G. H. M.
    Lakshmaiah, K.
    Roche, H. H.
    Sanchez-Rovira, P.
    Pienkowski, T.
    Segui-Palmer, M. A.
    Li, A.
    Sun, Y.
    Pickett-Gies, C. A.
    Wildiers, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345